Noticias Moderna Inc - MRNA | Acciones NASDAQ

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at...

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the...

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and...

Form 4 - Statement of changes in beneficial ownership of securities

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors PR Newswire CAMBRIDGE, Mass...

Form 8-K - Current report

MRNA LAWSUIT ALERT: The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

MRNA LAWSUIT ALERT: The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming...

axelvento 9 horas hace

HSBC upgrades to Buy on underestimated pipeline potential

👍️ 2 🤙 1

axelvento 1 día hace

Trump gives RFK Jr McDonald’s ‘poison’ to eat on private plane

https://www.yahoo.com/news/trump-gives-rfk-jr-mcdonald-133657991.html

👍️ 1 😴 1 🤣 1

axelvento 2 días hace

Bears need to take into consideration the CMV data coming our this quarter. It's a 3-5 TAM drug with no competitors
I'd be careful shorting this right now!

👍️ 1

Stock Guy777 3 días hace

Amen to that!

👍️0

axelvento 3 días hace

Kennedy’s spokesperson did not respond to my request for comment last night as to whether, as HHS secretary, RFK Jr. would move to outlaw any existing vaccines, and referred me to his victory-lap post on X, which did not mention the topic

https://www.theatlantic.com/politics/archive/2024/11/trump-health-human-services-nomination/680674/

clown-

👍️0

axelvento 3 días hace

I agree$$$$$$$$

👍️0

DewDiligence 4 días hace

He won't be confirmed by the Senate, in my opinion.

👍️ 2 🙏 1 🤞 1

Stock Guy777 4 días hace

By the looks of the chart it has been finished! This thing was well into the 300s when I traded it from $80’s to 300+ and now look at it!! Look Out below! Just decided to come back and take a look. It’s obviously done horrible as did the” Shot”

👍️ 1

Bountiful_Harvest 4 días hace

Vaccine Stocks Slide Further After Trump Taps RFK Jr. To Lead HHS; CNN Outraged

https://www.zerohedge.com/markets/vaccine-stocks-slide-further-after-trump-taps-rfk-jr-lead-hhs

Moderna is finished...

👍️ 1

Stock Guy777 4 días hace

Yeah, good for you. I played this back in the day. And got out. I was never a fan, just knew before the actual vaccine was created, that it would run up.

👍️0

Stock Guy777 4 días hace

Yeah, for the better! Finally stopping these Frankenstein doctors and their controversial “shots” that play havoc on your whole body that I believe potentially killed my father early

👍️ 1

spartex 4 días hace

Well right now it is having a huge impact on MRNA longs that are deeply under water if they haven't hedged with puts.

A four year low going all the way back to April 2020 period. Brutal. Glad I alerted the troops on this news yesterday to save themselves 7% or more downward draft today!

👍️0

axelvento 4 días hace

Trump’s latest controversial Cabinet pick could have a huge impact on Americans’ health and lives
https://edition.cnn.com/2024/11/15/politics/trump-rfk-cabinet-pick-american-health-analysis/index.html

the game$$$$$$$

👍️ 1 🤟 1

axelvento 4 días hace

RFK Jr. has built a reputation as a vaccine skeptic but has stopped short of adopting the “anti-vaxx” label attributed to him by critics. The former environmental lawyer has said his children are vaccinated and that he does not oppose safe vaccines.

relax$

👍️ 1 😃 1

axelvento 4 días hace

Kennedy has been one of the country’s most prominent anti-vaccine conspiracy theorists for years and has frequently spread falsehoods about the safety and efficacy of vaccines. Last week, Kennedy said he would “immediately” begin studying vaccine safety and efficacy but promised to not “take vaccines away from anybody.”

👍️0

Bountiful_Harvest 5 días hace

Shares of $MRNA and other hot shot stocks in full collapse on news of RFK joining the Trump admin

👍️0

spartex 5 días hace

Big selling all of a sudden. Sub $40 now. 52 week low.

Appears that Trump will nominate Rfk Jr. to Health and Human Services Admin.

https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617

😜 1

axelvento 5 días hace

next-
https://www.theguardian.com/society/2024/oct/23/doctors-trial-worlds-first-vaccine-against-vomiting-bug-norovirus

👍️ 4 🔜 1

Vexari 6 días hace

The majority shareholder of Moderna is?

When you are suffering

They are profiting

👇️ 1 🗑️ 1 🚽 1 🤪 1 🧻 1

axelvento 7 días hace

https://www.biospace.com/job-trends/biospace-announces-2025-best-places-to-work-in-biopharma

👋 1 👍 1

axelvento 1 semana hace

Jpmorgan Chase & Co ownership in MRNA / Moderna, Inc.
On November 8, 2024 - Jpmorgan Chase & Co filed a 13F-HR form disclosing ownership of 2,227,044 shares of Moderna, Inc. (US:MRNA) valued at $148,833,351 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 12, 2024 disclosing 1,756,708 shares of Moderna, Inc.. This represents a change in shares of 26.77% during the quarter. The current value of the position is $104,292,471 USD.

https://fintel.io/so/us/mrna/jpmorgan-chase-

👍 2

axelvento 1 semana hace

https://www.acsh.org/news/2024/11/07/dont-be-afraid-mrna-vaccines-49111

👍️ 3 🤙 1

axelvento 1 semana hace

Moderna Buys Norwood Campus for $400M

https://bankerandtradesman.com/moderna-buys-norwood-campus-for-400m/#:~:text=Lab%20developer%20Alexandria%20Real%20Estate,core%20properties%20in%20Greater%20Boston.

👍️ 3 😀 1

axelvento 2 semanas hace

Moderna (MRNA) Q3 2024 Earnings Call Transcript

https://www.fool.com/earnings/call-transcripts/2024/11/07/moderna-mrna-q3-2024-earnings-call-transcript/

👍️ 4 ✌️ 1

EarningsCentral 2 semanas hace

👍️0

axelvento 2 semanas hace

MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively

👍️0

axelvento 3 semanas hace

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

https://investors.modernatx.com/news/news-details/2024/Merck-and-Moderna-Initiate-Phase-3-Trial-Evaluating-Adjuvant-V940-mRNA-4157-in-Combination-with-KEYTRUDA-pembrolizumab-After-Neoadjuvant-KEYTRUDA-and-Chemotherapy-in-Patients-With-Certain-Types-of-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspx

huge news$

👍️ 1 🤑 1

axelvento 4 semanas hace

https://www.investing.com/news/company-news/piper-sandler-maintains-overweight-rating-on-moderna-stock-93CH-3680972

👋 1 👍️ 2

axelvento 4 semanas hace

20B market cap, 10B in cash, high potential pipeline in 4 therapeutic areas!

👍️ 2 💪 1

axelvento 4 semanas hace

Moderna has a whopping 33 million short share interest, but daily volume now a paper-thin 3.7 million

"Highest shorted stock on S&P500"

👍️ 1 🤣 1 ☝️ 1

axelvento 4 semanas hace

MRNA December 6th Options Begin Trading

https://www.nasdaq.com/articles/mrna-december-6th-options-begin-trading

👍️0

axelvento 4 semanas hace

Moderna’s norovirus vaccine enters Phase III trials in the UK
The firm hopes to file marketing applications in 2026 to have the vaccine approved by health regulators.

https://www.clinicaltrialsarena.com/news/modernas-norovirus-vaccine-enters-phase-iii-trials-in-the-uk/

👍️ 2 🤙 1

Vexari 4 semanas hace

Depends

On the road

That they're on

👎️ 1 🗑️ 1 🚽 1 🧻 1 0️⃣ 1

Vexari 4 semanas hace

All that is marketed

Is fear based

🌬️ 1 🎃 1 👎️ 1 🕳️ 1 🗑️ 1

gapole 4 semanas hace

looks like meltdown here. where is the bad news? $53.54

👍️0

Monksdream 1 mes hace

MRNA new 52. Week low

👍️0

axelvento 1 mes hace

Moderna stock touches 52-week low. bouncer

👍️0

axelvento 1 mes hace

https://www.kcl.ac.uk/news/mrna-cancer-vaccine-potential-advanced-stage-cancer-patients-in-phase-1-trial

👍️ 1 ✌️ 1

jondoeuk 1 mes hace

I couldn't find a PR or the poster.

👍️0

Vexari 1 mes hace

Unraveling all the Lies of the Covid-19

Psychological Operation

👎️ 2 🗑️ 1 😎 1 🤥 1 🧻 1 0️⃣ 1

axelvento 1 mes hace

$MRNA We are tackling cancer on an individual basis where we can take samples from each patient, understand their cancer, and design a therapy specifically for them

https://www.fastcompany.com/91202048/the-mrna-advantage

👍️ 1 🫨 1 ☝️ 1

tmonkey 1 mes hace

this one near a bottom-im in------tmonkey

👍️0

axelvento 1 mes hace

https://www.globenewswire.com/news-release/2024/10/04/2958235/0/en/Global-mRNA-Cancer-Vaccine-Clinical-Trial-FDA-Approval-Market-Size-Future-Opportunity-Companies-Insight.html

$MRNA

👍️ 1 🤑 1

axelvento 2 meses hace

Join us on Nov 8, as we, alongside
moderna_
, share promising data on anti-GPC3 in vivo CAR-M therapy for HCC. We'll also present TIP poster for the Ph1 study of anti-HER2 CAR-Monocytes targeting solid tumors.

https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-announces-upcoming-presentations-sitc-2024

👍️ 1 😃 1

axelvento 2 meses hace

back to the 23 November lows bounce spot watching either way to see if holds or breaks.

👍️0

axelvento 2 meses hace

We have put the mescaline to make you feel better-have a good trip$MRNA

👍️ 2 😀 1

axelvento 2 meses hace

With post hoc analysis....

👍️ 2 🤑 1

Vexari 2 meses hace

What's in this dose of Pivotal

How does it affect the immune system

Why not question what is being announced

Instead of grabbing onto it

Hook line and sinker

👎️ 1 🗑️ 1 🤪 1 🧻 1 0️⃣ 1

axelvento 2 meses hace

Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403

https://investors.modernatx.com/news/news-details/2024/Moderna-Announces-First-Participant-Dosed-in-Pivotal-Phase-3-Trial-of-Investigational-mRNA-Norovirus-Vaccine-mRNA-1403/default.aspx

👍️ 1 ✌️ 1

axelvento 2 meses hace

Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

https://investors.modernatx.com/news/news-details/2024/Moderna-and-Cenra-Healthcare-Enter-Joint-Agreement-to-Promote-Modernas-mRNA-Respiratory-Vaccine-Portfolio-in-Taiwan-Including-COVID-19-Vaccines/default.aspx

👍️0

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Moderna Inc (MRNA)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

MRNA Noticias

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Form 4 - Statement of changes in beneficial ownership of securities

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Form 8-K - Current report

MRNA LAWSUIT ALERT: The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

MRNA Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Moderna Inc (MRNA) Noticias

Moderna Inc (MRNA)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

MRNA Noticias

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Form 4 - Statement of changes in beneficial ownership of securities

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Form 8-K - Current report

MRNA LAWSUIT ALERT: The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

MRNA Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación